19:55 , Apr 11, 2019 |  BC Innovations  |  Emerging Company Profile

Nurix: Two sides of protein degradation

Nurix is flipping the concept of targeted protein degradation on its head. In addition to the usual approach of inducing target destruction, the company has technology that can block E3 ligase activity and increase a...
17:40 , Oct 19, 2018 |  BC Week In Review  |  Company News

Revolution acquiring Warp Drive

Revolution Medicines Inc. (Redwood City, Calif.) is expanding its cancer pipeline with the acquisition of another Third Rock Ventures portfolio company, Warp Drive Bio Inc. (Cambridge, Mass.). The financial terms of the deal are undisclosed...
22:17 , Oct 16, 2018 |  BC Extra  |  Company News

Revolution acquiring fellow Third Rock company Warp Drive

Revolution Medicines Inc. (Redwood City, Calif.) is expanding its cancer pipeline with the acquisition of another Third Rock Ventures portfolio company, Warp Drive Bio Inc. (Cambridge, Mass.). The financial terms of the deal are undisclosed...
23:05 , Aug 1, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: July 2018

New Therapeutic Targets and Biomarkers: July 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during July 2018. Therapeutic targets are defined as any protein, gene or other...
15:41 , Jul 18, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling Mutations in hematopoiesis-associated genes could help predict the risk of AML. Genomic sequencing of 124 patients who later developed AML and 686 healthy volunteers identified associations between the disease and mutations in...
17:36 , Jul 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC) Cell culture and mouse studies suggest inhibiting CBLC could help treat EGFR-mutant NSCLC. In two human EGFR-mutant NSCLC cell lines, two shRNAs targeting CBLC decreased viability compared with a...
19:13 , May 18, 2018 |  BC Week In Review  |  Financial News

Stapled peptide company FOG raises $66M series B

FOG Pharmaceuticals Inc. (Cambridge, Mass.) raised $66 million in a series B round led by 6 Dimensions Capital. New investors GV, Blue Pool Capital, Horizons Ventures, Nan Fung Group and Leerink Partners also participated, as...
12:01 , May 16, 2018 |  BC Extra  |  Financial News

Stapled peptide company FOG raises $66M series B

FOG Pharmaceuticals Inc. (Cambridge, Mass.) raised $66 million in a series B round led by 6 Dimensions Capital. New investors GV, Blue Pool Capital, Horizons Ventures, Nan Fung Group and Leerink Partners also participated, as...
20:53 , Oct 4, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: September 2017

New Therapeutic Targets and Biomarkers: September 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during September 2017. Therapeutic targets are defined as any protein, gene or other...
20:18 , Sep 22, 2017 |  BC Week In Review  |  Clinical News

Mirati reports partial responses in Phase II NSCLC trial of sitravatinib

Mirati Therapeutics Inc. (NASDAQ:MRTX) reported preliminary data from a Phase II trial showing that sitravatinib (MGCD516) in combination with PD-1 mAb Opdivo nivolumab led to 3 confirmed partial responses in 11 evaluable patients with non-squamous...